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ttp://dx.doi.org/10.1016/j.ajpath.2013.04.033In cancer, the overall patterns of epigenetic marks are severely distorted from the corresponding normal
cell type. It is now well established that these changes can contribute to cancer development through
inactivation of tumor suppressor genes and, conversely, through activation of oncogenes. Recent
technological advances have enabled epigenome-wide analyses of cancers that are yielding unexpected
ﬁndings. The study of cancer epigenetics holds great promise for expanding the range of therapeutic
opportunities for personalized medicine. Here, we focus on DNA methylation in breast cancer and the
potential implications for clinical management of patients. (Am J Pathol 2013, 183: 1052e1063;
http://dx.doi.org/10.1016/j.ajpath.2013.04.033)Supported by the Health and Science Departments of the Catalan Govern-
ment (Generalitat de Catalunya). M.E. is an ICREA Research Professor.
This article is part of a review series on themolecular pathogenesis of breast
cancer.Breast cancer is the most common cancer among women
and ranks among the top ﬁve leading causes of cancer-
related deaths, according to the World Health Organization
(http://www.who.int/mediacentre/factsheets/fs297/en; reviewed
January 1, 2013). Inherited and acquired mutations in genetic
material are known to be important contributors to the
development of breast cancer. Indeed, family history is the
strongest risk factor for developing breast cancer, for which
germline mutations in the BRCA1, BRCA2, and TP53 (alias
p53) genes are known to be high-risk factors.1 Several other
inherited mutations and genetic variations have been identi-
ﬁed as risk factors conﬁrmed by independent researchers,
although their effects are estimated to be either moderate or
low.2 Soon after the discovery that BRCA1 and BRCA2 are
high-risk breast cancer susceptibility genes, functional
studies consistently identiﬁed their gene products as com-
ponents critical to the repair of double-stranded DNA breaks
(DSBs).3 The subsequent hypothesis was that defects in the
DNA repair machinery due to mutations in BRCA1, BRCA2,stigative Pathology.
.or other repair genes would accelerate the rate of randomly
occurring mutations and that this would, in a step-by-step
manner, lead to clonal outgrowth of tumor cells with
acquired mutations advantageous to the tumor. This
emphasizes the classical view that cancer, including breast
cancer, is a genetic disease. However, researchers are
increasingly recognizing that epigenetic changes, as well as
genetic mutations, are critical contributors to the develop-
ment of cancer.4,5
The body of evidence supporting the involvement of
epigenetic changes in promoting cancer development has
been growing since the early 1990s, when renal cell carci-
nomas arising without mutations in the VHL gene (alias
VHL1) were found to have epigenetic inactivation of VHL.6
Figure 1 Epigenetic marks inﬂuence expression potential by inducing
modiﬁcations to chromatin conﬁgurationat genepromoter regions by affecting
the accessibility of transcription factors. A: CpG islands of actively transcribed
genes are unmethylated and have epigenetic marks attached to histones
ﬂanking the promoter region to induce states of open chromatin conﬁguration,
which prevent nucleosomes from occupying the promoter region. These marks
include histone tail modiﬁcations involving trimethylation at histone H3 lysine
residue K4 (H3K4Me3) and extensive acetylation on lysine residues at histones
H3andH4.B: Epigenetic gene inactivationby CpG island promotermethylation
is frequently associated with histonemodiﬁcations involving trimethylation of
lysine residue K27 or trimethylation of lysine residue K9 at histone H3, coupled
with loss of the active marks H3K4Me3 and acetylated H3 and H4. Importantly,
nucleosomes spread over the promoter region and across the transcriptional
start site, leading to closed chromatin conﬁguration and repressed transcrip-
tion due to reduced accessibility of transcription factors.
Epigenetics and Breast CancerMore recent discoveries include that of acquired mutations in
ARID1A (involved in chromatin remodeling), which occur in
approximately half of all ovarian cancers.7 Indeed, acquired
mutations in ARID1A have now been found in other types of
cancer, including breast cancers.8 Other examples of mutated
epigenetic genes (ie, genes involved in establishing and
maintaining epigenetic patterns) include IDH1 mutations in
glioblastoma9 and MLL3 or MLL2 (reclassiﬁed as KMT2
genes) mutations in breast cancer.10 Recently, targeted inac-
tivation of tumor suppressor genes by epigenetic mechanisms
has been found to induce cancer under controlled experi-
mental conditions using human mesenchymal cells.11 In
sporadically arising breast and ovarian cancers, the BRCA1
gene is recurrently inactivated by epigenetic mechanisms.12,13
This ﬁnding has been conﬁrmed in multiple independent
studies and, given that BRCA1 is a well-known susceptibility
gene, the ﬁnding strongly supports the hypothesis that epige-
netic modiﬁcations, as well as genetic mutations, contribute to
the development of breast cancer.14e16 Other examples of
epigenetically inactivated DNA repair genes includeMGMT in
glioblastomas,17 WRN in cervical cancer,18 and MLH1 in
colorectal and endometrial cancers.19,20 Thus, not only do we
now know that somatically acquired mutations arise from the
acquired epigenetic repression of DNA repair genes, but also
that many epigenetic genes are recurrently and signiﬁcantly
mutated in various cancers. In this review, we focus on DNA
methylation in breast cancer and discuss potential implications
for clinical practice.
Epigenetic Modiﬁcations
The genetic material is organized within the nucleus by the
DNA helix wrapping around histone proteins. The structural
organization of this DNAehistone complex, known as chro-
matin, is regulated by epigenetic factors involving DNA
methylation and various types of histone marks and noncoding
RNAs.21 The term epigenetics refers to heritable states of gene
expression that are not attributed to the DNA sequence. DNA
methylation, a well-known epigenetic mark, occurs at cytosine
residues where cytosine (C) precedes a guanine (G) residue,
known as CpG dinucleotides (where p stands for the phos-
phodiester bond connecting cytosine and guanine).22 The
distribution of CpGs is not random; genomic regions enriched
in CpGs, known as CpG islands, are often found at gene
promoter sequences. CpG islands characterize the promoter
region of more than half of all genes in the human genome.23 It
is thought that the overall reduction in genomic CpGs has
occurred over evolutionary time and that it relates to the
spontaneous or enzymatic deamination of methylated cytosine
residues in the germline and thereby conversion to thymine.
Transcriptionally active genes are depleted in DNA methyla-
tion at their gene promoter CpG islands and, in this case, the
ﬂanking nucleosomes are often marked with trimethylation at
histone H3 on lysine residue K4, known as the H3K4Me3
mark, while also containing the histone variant H2A.Z and
acetylated lysine residues on histones H3 and H4. TheseThe American Journal of Pathology - ajp.amjpathol.orgfeatures are thought to reduce the formation of nucleosomes,
thereby leading to a stable nucleosome-depleted region that is
characteristic of actively transcribed genes (Figure 1).
It is now becoming clear that DNA demethylation can be
achieved through the activity of the TET enzymes (ten-eleven
methylcytosine dioxygenases) which convert methylated
cytosines into hydroxymethylated cytosines (5hmC).24 In one
model, the 5hmCs are not maintained during cellular division,
but are instead interpreted by the replication machinery as
unmethylated cytosines and are propagated as such leading to
passive demethylation. Another model, however, holds that
5hmCs are one type of many intermediates catalyzed by the
TET enzymes and that these intermediates can be replacedwith
unmethylated cytosines without the need for cellular division
through the activity of a DNA repair pathway known as base-
excision repair. This mechanism of active DNA demethyla-
tion is of potential relevance in maintaining CpG islands in
unmethylated states. The discovery of mutations in the TET2
gene in acute myeloid leukemia highlights the importance of
these genes and their functionality in cancer biology.25
In normal cells, CpG island methylation occurs infre-
quently and affects only a small number of autosomal genes,
of which most are involved in developmental processes. Our
research group conﬁrmed CpG island methylation by DNA
methylation proﬁling of 424 normal human tissue samples of1053
Table 1 Selected Examples of CpG Island Promoter Hypermethylated Genes in Breast Cancer, Demonstrating Diverse Biological Implications
Gene
symbol Gene name Known function References
BRCA1 Breast cancer 1, early onset DNA damage response 13,14,16
CDH1* Cadherin 1, type 1, E-cadherin
(epithelial)
Cell-to-cell adhesion 29
RARB2 Retinoic acid receptor, beta Embryonic morphogenesis, regulation of expression, and negative
regulation of cellular proliferation
29,30
CDKN2A Cyclin-dependent kinase inhibitor 2A G1 phase of the mitotic cell cycle, cellular senescence and apoptosis 29,31
PTEN Phosphatase and tensin homolog PI3KeAKT signaling pathway, negative regulation of cellular proliferation 32,33
RASSF1y Ras association (RalGDS/AF-6)
domain family member 1
Signal transduction, cell cycle arrest, and response to DNA damage stimulus 33
RUNX3 Runt-related transcription factor 3 Transcription factor involved in development and regulation of mitosis 34,35
ESR1 Estrogen receptor 1 Epithelial cell development, sexual development, and reproductive function 36
PITX2 Paired-like homeodomain
transcription factor 2
Wnt receptor signaling pathway 37
GSTP1 Glutathione S-transferase pi 1 Detoxification 32,38,39
*CDH1 has been reclassiﬁed as ﬁzzy/cell division cycle 20 related 1 (Drosophila) (FZR1).
yAlias RASSF1A.
Stefansson and Estellervarious types, and further showed that CpG sites located at
the non-CpG island 50 ends best discriminate tissue-speciﬁc
differences in terms of DNA methylation.26 Indeed, in that
study the different tissue types in the human body were
shown to have clear differences in their epigenome-wide
DNA methylation patterns. DNA methylation, especially at
CpG islands, is generally thought to involve long-term
silencing of genes such as those on the inactive X chromo-
some, imprinted genes, and genes expressed only in germ
cells.22 It is thought thatCpG islandgenepromotermethylation
functions to stabilize gene silencing after histone modiﬁca-
tions. In this sense, repressive histone marks are applied before
CpG island methylation, in what has sometimes been referred
to as the locking model of epigenetic gene silencing.
The intragenic regions of transcribed genes (ie, gene
bodies) exhibit CpGmethylation but are marked with histone
H3 trimethylation at K36. The differential methylation
between promoter regions and gene bodies supports the
emerging view that the position of CpG methylation within
the promoter is critical to understanding the relationship of
methylation and gene expression activity. For example, CpG
island promoter methylation tends to block transcription
initiation, whereas gene-body methylation does not.22 The
function of gene-body methylation is not clear, although it
may perhaps protect against major sources of mutagens such
as endogenous reactive oxygen species and suppress intra-
genic retrotransposons such as LINE1 or Alu elements.
Nevertheless, the presence of gene-body methylation comes
at the price of the aforementioned deamination of methylated
CpGs, which increases the risk of genetic mutations from
cytosine to thymine residues. This type of mutation is
commonly seen in known cancer genes such as TP53 and
is therefore thought to be an important mechanism by
which mutations arise and sometimes contribute to the
development of cancer.27 Recent data have demonstrated that
the H3K9Me3 repressive histone marker, a marker of
constitutive heterochromatin, is associated with increased1054mutation density in various types of cancers.28 This ﬁnding
reinforces the notion that the epigenetic organization of the
human genome can inﬂuence the rate of acquired mutations
relevant to the development of cancer.
Epigenetic Modiﬁcations in Cancer
In the development of cancer, epigenetic mechanisms are
important in terms of both silencing of tumor suppressor
genes and activation of oncogenes.4 Both silencing and acti-
vation occur through changes in chromatin conﬁguration by
which the accessibility of transcription factors is affected,
with consequences for gene expression. In breast cancer,
tumor suppressor genes such asBRCA1,CDKN2A, andPTEN
undergo CpG island promoter methylation, but in normal
cells the promoter region is unmethylated. The functional
roles of genes inactivated by epigenetic mechanisms in breast
cancer and other types of cancers are diverse and reﬂect
various cancer hallmarks (Table 1). Hon et al40 recently
described a novel mechanism of epigenetic gene inactivation
through hypomethylation of gene bodies without involving
CpG island promoter hypermethylation (discussed below).
The polycomb group (PcG) protein complex 2 has well-
established roles in applying trimethylation to histone H3 at
lysine residue 27; this H3K27Me3 mark is recruited to target
genes by JARID2, where it induces repressed chromatin
conﬁgurations.41 In a study of the landscape of histone
modiﬁcations in embryonic stem cells, the H3K27Me3
repressive mark was unexpectedly found to co-occur with the
H3K4Me3marker of active transcription.42 This state, known
as a bivalent chromatin state, is thought to be important for
maintaining pluripotency by silencing the genes necessary for
inducing differentiation while also keeping them poised for
activation later in the differentiation process. Interestingly,
EZH2 gene products, which are components of the PcG
protein complex 2, appear to mark genes that are prone to
DNA methylation in some subtypes of gliomas, breastajp.amjpathol.org - The American Journal of Pathology
Epigenetics and Breast Cancercancers, and other types of cancer.43 In recent years, non-
codingRNAs 44 have increasingly been recognized as helping
to establish global patterns of PcG occupancy [(eg, HOTAIR
andCDKN2B-AS1 (alias ANRIL)], and it is therefore possible
that noncoding RNAs have roles in determining cancer-
speciﬁc patterns of DNA methylation.45Epigenome-Wide Views of Breast Cancers
In a recent study using DNA methylation proﬁling of
normal and diseased tissue samples, including several types
of cancer, our research group found distinct patterns of
DNA methylation associated with each cancer type.26 The
patterns persisted even after we subtracted CpG sites asso-
ciated with distinct types of normal tissues. Similar differ-
ences in breast cancer subtypes have been described,46 and
some researchers have even found evidence of a CpG
methylator phenotype within luminal subtypes,47 whereas
the basal-like subtype seems to have fewer overall gains in
CpG methylation.48 Fang et al47 reported a favorable prognosis
in relation to the methylator phenotype in different cancer
types, including breast cancers. Our research group explored
the process of cancer progression, based on the analysis of
precancerous lesions together with primary cancers; we found
a trend toward progressive gains in CpG methylation within
CpG islands, whereas the global loss of CpG methylation
became increasingly more prominent at non-CpG islands.26
Whole-genome bisulﬁte sequencing, which provides
single-nucleotide resolution of DNA methylation, has
revealed that CpGs methylated in pluripotent cells are
always completely methylated, whereas in differentiated
cells methylated CpGs can be found in partially methylated
states.49 Interestingly, in differentiated cells there are large
continuous regions, the so-called partially methylated
domains (PMDs), which usually contain repressed genes.
PMDs span approximately 40% of the genome, which
indicates that the differentiation process is indeed accom-
panied by substantial modiﬁcations of the DNA methylation
landscape. Nonetheless, we currently have a poor under-
standing of the relevance of PMDs and of how they come
about during differentiation. Lister et al49 described an
important role for non-CpG methylation in embryonic stem
cells, which raises questions about the signiﬁcance of non-
CpG methylation changes in cancers. Hon et al,40 in
a study using whole-genome bisulﬁte sequencing in a breast
cancer cell line (HCC1954) and in other cancer types,
demonstrated that cancer-speciﬁc methylation events are
almost entirely conﬁned to the CpG context. Interestingly,
their study demonstrated that cancer-speciﬁc changes, either
gains or losses in CpG methylation, tend to occur in PMDs.
An unexpected ﬁnding was that of large-scale hypo-
methylation in association with repressed gene expression
activity. This change involves aberrant unmethylated CpG
states at gene bodies containing repressive histone marks
with the homologous alleles that are methylated in the geneThe American Journal of Pathology - ajp.amjpathol.orgbody and promoter regions, thereby resulting in transcrip-
tional repression. Thus, by establishing a link between gene
body hypomethylation and the formation of heterochro-
matin, the study of Hon et al40 has already led to advanced
knowledge on the functional consequences of hypo-
methylation in cancer. According to their results, gene body
hypomethylation appears to involve the lack of methylation
maintenance after cellular division. The mechanism leading
to the formation of heterochromatin, however, remains to be
clariﬁed. It should be emphasized here that the HCC1954 cell
line in the Hon et al40 study is classiﬁed as basal-like, which is
a subtype accounting for only approximately 15%of all breast
cancers. Furthermore, basal-like breast cancers undergo
relatively few CpG methylation events, compared with other
subtypes.49 In contrast, the hormone receptor-positive
subtypes are more prone to CpG island methylation, which
occurs predominantly at PcG-regulated genes,46,47 consistent
with the idea that the PcG proteins are involved in estab-
lishing DNA methylation.43Epigenetic Changes Contribute to Genetic
Mutations in Breast Cancers
Breast cancer genomes usually contain thousands of genetic
changes, of which only a small subset might actually drive
development of the disease.50 In some cases, only a few
mutations are found, reﬂecting the slow accumulation of
acquired mutations over the lifetime of the individual. Other
cases exhibit a large number of mutations, suggesting that
DNA repair capacity has been affected, coupled with induc-
tion of genetic instability. This occurs in breast cancers arising
in BRCA1 and BRCA2mutation carriers, in whom the loss of
the second wild-type allele is generally thought to be an
important event leading to breast cancer development.51,52
CpG island promoter hypermethylation, as a mechanism of
gene inactivation, is only infrequently found as the second
hit in familial BRCA1- or BRCA2-mutated breast cancers.29
Nevertheless, other tumor suppressor genes, including
CDKN2A (alias p16),FZR1 (aliasCDH1),RARB2, andGSTP1
undergo CpG island hypermethylation at more or less similar
frequencies inbreast cancers arising in familial cases (including
BRCA1 and BRCA2 mutation carriers) and in those arising
sporadically.29 Thus, epigenetic changes are needed even in
cancers with DNA repair dysfunction (ie, in breast cancers
arising inBRCAmutation carriers). Thisﬁnding illuminates the
important role of epigenetic changes in addition to genetic
mutations as contributors to the development of breast cancer.
Given the prevalence ofmutations inTP53 in breast cancer and
other cancer types, many researchers have studied epigenetic
changes in this gene, but none have reported inactivation by
CpG island promoter hypermethylation or other types of
repressive epigenetic modiﬁcations.53
It is now well established that CpG island hyper-
methylation of the BRCA1 gene promoter region occurs in
approximately 10% to 15% of all sporadic breast cancers.1055
Stefansson and EstellerMost researchers have found that BRCA2 methylation does
not occur,54 although this is still debatable.55,56 Other DNA
repair genes, including PALB2 and ATM, have been reported
to be epigenetically inactivated by CpG island promoter
hypermethylation in breast cancers,57,58 although these
ﬁndings are yet to be conﬁrmed by other researchers.59 In
contrast, there is strong support for BRCA1 methylation in
sporadic breast cancer development. There are clear pheno-
typic effects associated with breast cancers arising in BRCA1
mutation carriers, and the effects similarly characterize
sporadic breast cancers with acquired BRCA1methylation. In
these cases, the second hit is thought to be acquired genomic
deletions of the wild-type and unmethylated allele.14,57 With
respect to the phenotype, it has been demonstrated that
primary breast cancer cells with BRCA1 gene defects, caused
by either inherited mutations or acquired promoter methyl-
ation, tend to be poorly differentiated. Additionally, BRCA1
dysfunctional breast cancers lack expression of estrogen and
progesterone receptors, but express basal-like markers such
as CK5/6 and EGFR.60,61
The link between BRCA1 defects and the basal-like
phenotype probably reﬂects an important role of the
BRCA1 gene in differentiating somatic stem cells of the
breast.62 Indeed, researchers have demonstrated that loss of
BRCA1 gene products preferentially leads to the trans-
formation of luminal progenitor cells with phenotypic simi-
larities to the basal-like phenotype.63 In addition to the
similar expression patterns, sporadic breast cancers with
acquired BRCA1 methylation have extensive DNA copy
number changes suggestive of instability, similar to those
observed in breast cancers arising in BRCA1 mutation
carriers.64,65 This probably reﬂects defective DNA repair of
DSBs and, consequently, accelerated mutation rates due to
unrepaired breaks and the use of error-prone DNA repair
processes involving nonhomologous end joining. The char-
acteristic mutational patterns predicted to emerge from
nonhomologous end joining include large-scale structural
changes (ie, deletions, gains, or translocations), as well as the
formation of so-called indels, which are mutations involving
a few base pairs erroneously deleted or inserted. Mutations of
the indel type have been described in PTEN, RB1, and TP53.
All three are well-known tumor suppressor genes, associated
with breast cancers arising in BRCA1 mutation carriers and
sporadic breast cancers with acquired BRCA1 methylation
and those exhibiting the basal-like phenotype.66e68 Thus,
understanding why acquired mutations arise and lead to
cancer inevitably involves the study of epigenetic modiﬁca-
tions. It is important to keep epigenetic modiﬁcations in mind
when considering acquired mutations as predictors of drug
response (discussed below).
Data are emerging to support the involvement of the
histone methyltransferase EZH2 in inducing epigenetic
silencing of RAD51 (a well-known DNA repair gene).69,70
The H3K27Me3 repressive marker was found at the
promoter region of RAD51 after induced expression of the
EZH2 gene,69 and EZH2 expression was shown to be1056associated with activation of RAF1eMEK signaling and
expansion of breast cancer stem cells.70 Consistent with an
important early event and carcinogenic potential, the targeted
overexpression of EZH2 in mammary glands of mouse
models leads to disruption of ductal morphogenesis and
precancerous lesions.71 The link to expansion of cancer stem
cells in the breast suggests a mechanistic link to aggressive
behavior in breast cancer patients. Indeed, a high level of
expression of the EZH2 gene has been described in associa-
tionwith basal-like and luminal-B subtypes, both ofwhich are
known to be poorly differentiated subtypes associated with
unfavorable disease outcome.72 Additionally, the EZH2 gene
product is known to be recruited to sites of DSB damage, in
conjunction with other PcG proteins, such as BMI1, and the
NuRD complex.73 This recruitment occurs very early, and
may function to establish the repressed chromatin conﬁgu-
ration at the damaged sites to prevent transcription. Interest-
ingly, CBX1 (alias HP1-b) gene products, which are
chromodomain-containing proteins functionally implicated
in reading the histone code, are rapidly mobilized from DSB
sites shortly after damage occurs.74 This is important for
subsequent repair, because phosphorylation of H2AX (an
essential signal for inducing the recruitment of DNA repair
proteins) does not occur at sites occupied by HP1-b. Thus,
sensing of DSBs is critically dependent on the dynamic
reorganization of chromatin structure to facilitate the repair
process.
Finally, the pattern of epigenetic marks surrounding the
lesion needs to be re-established. This implies that the
epigeneticmachinery has a direct role inmaintaining genomic
stability, which suggests a therapeutic potential in breast
cancers with dysfunctional DSB repair processes or, alter-
natively, the sensitization of cancer cells to DNA-damaging
agents. Of interest in this respect are the ﬁndings of Puppe
et al,75 who used murine breast cancer cell line models to
demonstrate that targeted disruption of the BRCA1 gene leads
to cellular sensitivity to inhibitors of EZH2 gene products.The Central Role of BRCA1 Methylation in
Predicting Treatment Response and in
Personalized Medicine
In personalized medicine, decisions about drug treatment
are tailored to each patient on the basis of which cancer
genes are affected in the primary cancer.76 This concept is
based on the idea that some cancer genes harboring genetic
changes are predictive of patient response to speciﬁc anti-
cancer drugs, such as BRCA1 or BRCA2 mutations in rela-
tion to PARP inhibitors [eg, olaparib (AZD-2281)] or
PIK3CA mutations in relation to PI3K inhibitors. Rese-
quencing of a large number of cancer cell line models has
recently been conducted and analyzed with respect to drug
sensitivity.77,78 The resulting reports, although supporting
the validity of using mutated cancer genes as predictors for
drug response, describe many previously unexpectedajp.amjpathol.org - The American Journal of Pathology
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that are worthy of further investigation. Given that most
cancer genes are only infrequently mutated, it is likely that
personalized medicine could be applied to a larger number
of patients if epigenetic changes as well as mutations were
considered. For example, breast cancers arising in BRCA1
and BRCA2 mutation carriers affect a minority of patients
(fewer than 5%), whereas sporadically arising breast cancers
with acquired BRCA1 methylation account for 10% to
15% of all patients.14,16 By taking into account epigenetic
changes, more patients than just the mutation carriers could
derive beneﬁts from treatments based on targeting deﬁ-
ciencies for either BRCA1 or BRCA2. In this context, the use
of speciﬁc anticancer drugs predicted to be effective against
cancers with defective DSB repair mechanisms is highly
relevant.79,80 Anticancer drugs leading to the formation of
DSBs, such as platinum-based drugs, have been tested for
breast cancer, because this treatment is predicted to be
effective in killing BRCA1- or BRCA2-defective cells.
PARP inhibitors have shown their effectiveness against
cancer cells with defects in DNA repair of DSBs.81,82 These
inhibitors block the activity of PARP enzymes, of which
PARP-1 is an important target involved in signaling the pres-
ence of single-strand breaks. The inhibition of PARP-1 there-
fore leads to more unrepaired single-strand breaks. The
presence of single-strand breaks at replication forks leads to the
formation of DSBs that cannot be repaired in BRCA1- or
BRCA2-defective cells, thereby leading to the accumulation of
DSBs and to cellular death. This is known as synthetic lethality,
inwhich cellular death results from the blocking of two ormore
pathways, but blocking of only one does not affect cellular
survival (although phenotypic effects may arise).83Figure 2 Epigenetic changes contribute to the development of breast cancer and
promoter regions of tumor suppressor genes, such as the BRCA1 gene, are unmethyla
enables translation, which in turn facilitates its normal biological activity, such as
During carcinogenesis, epigenetic changes can contribute to the inactivation of tum
in conjunction with the accelerated formation of acquired mutations leads to cance
patient’s speciﬁc gene aberrations. In this case, CpG island promoter hypermethyla
techniques such as methylation-speciﬁc PCR. The presence of acquired CpG island pro
the patient will respond to DNA-damaging drugs such as PARP inhibitors, or platin
The American Journal of Pathology - ajp.amjpathol.orgInitial testing of PARP inhibitors in clinical trials involved
the use of olaparib, which successfully induced pathological
responses in breast cancer patients with inherited mutations in
either BRCA1 or BRCA2.84,85 The effectiveness of the drug in
patients with inherited BRCA1 or BRCA2 mutations raised the
question of whether this drug could also be useful in some
sporadically arising breast cancers. Based on the phenotypic
similarities between BRCA1-mutated breast cancers and basal-
like breast cancers,86 PARP inhibitors were tested in patients
with triple-negative (TN) sporadic breast cancers. The TN
phenotype [ie, breast cancers negative for the expression of
estrogen and progesterone receptors and lacking ERBB2 (alias
HER2) ampliﬁcation] signiﬁcantly coincides with that of the
basal-like phenotype; TN breast cancers are basal-like, and vice
versa.87 Because inherited mutations in the BRCA1 gene pref-
erentially result in the development of basal-like breast cancers,
acquired defects in theBRCA1 gene, or in other geneswithin the
same pathway, might also be found in sporadic cases of basal-
like or TN breast cancers. Testing PARP inhibitors in TN
breast cancers initially gave promising results,88 but subsequent
trials failed to conﬁrm these ﬁndings. The PARP inhibitor used
in that study, iniparib, was later found to be ineffective in
blocking the activity of the PARP-1 enzyme.89 Thus, it is still
not known whether PARP inhibitors could be useful in this
subset of sporadic breast cancer patients or only in the small
group of patientswith inheritedmutations inBRCA1 orBRCA2.
Nonetheless, the genetic heterogeneity of basal-like breast
cancers (and TN breast cancers) was recently brought into
sharp focus,90 and only a subset of these tumors show signs
of BRCA1 deﬁciency.48 In terms of epigenetic aberrations,
our research group showed that approximately half of all TN
breast cancers have acquired BRCA1 methylation,60 and thatmay have implications for personalized medicine. In normal cells, CpG island
ted and nucleosome depleted, thereby enabling transcription initiation. This
BRCA1 gene products performing DNA repair to maintain genomic integrity.
or suppressor genes. In this example, BRCA1 CpG island promoter methylation
r. In personalized medicine, treatment decisions are based on the individual
tion of the BRCA1 can be detected with simple, fast, and low-cost epigenetic
moter hypermethylation of BRCA1 enables clinical oncologists to predict that
um-based drugs. M, methylated; U, unmethylated.
1057
Stefansson and Estellerthis epigenetic marker is a good predictor of response to
PARP inhibitors in breast cancer cell line models.91 The use
of BRCA1 methylation as a predictor of therapeutic response
to PARP inhibitors was subsequently conﬁrmed in xeno-
graft tumor models.92 These preclinical data, along with
contributing to a clear mechanistic understanding, provide
a strong rationale for including BRCA1 methylation in
clinical trials as a candidate predictor of response to PARP
inhibitors (Figure 2).
Other drugs of potential relevance include platinum-based
agents, such as cisplatin. These drugs exert their effectiveness
by inducing the formation of cross-links. These types of
lesions are ineffectively repaired in BRCA1- and BRCA2-
defective cells, because they involve the formation of
DSBs.93 Consistent with this notion, ovarian cancer patients
with inherited mutations in either BRCA1 or BRCA2 respond
better than noncarriers to platinum drugs.94,95 Mutations in
the TP53 gene, however, appear to be associated with
resistance to cisplatin treatment.96 In contrast, we demon-
strated that this type of treatment is effective in breast cancer
cells and xenografts with acquired BRCA1 methylation.97 As
already noted, TN breast cancer patients have a higher inci-
dence of BRCA1 gene dysfunctions, because of BRCA1
methylation in sporadic cases or BRCA1mutations in familial
cases. This probably explains the generally good response to
platinum-based treatment in TN breast cancer patients.98 In
support of this hypothesis, BRCA1 methylation has been
found to predict signiﬁcantly higher response rates to
cisplatin treatment in patients with TN breast cancer.99
Finally, a prospective phase II clinical study of 20 patients
with metastatic breast cancer and inherited BRCA1 mutation
demonstrated high activity of cisplatin treatment.100
The use of platinum-based treatment has already been
approved for use in breast cancer and, based on the high
pathological response rates reported by Byrski et al,100 it is
reasonable to ask (as Turner and Tutt101 do) whether clini-
cians should need any further evidence to change standard
clinical practice in the treatment of BRCA1mutation carriers.
The speciﬁc importance of selecting platinum-based drugs as
the ﬁrst-line treatment for patients with BRCA1 dysfunctional
breast cancers has to do not only with increased response
rates, but also with resistance to other types of drugs, such as
anthracyclines and taxanes.102,103 Selecting platinum-based
drugs, or possibly PARP inhibitors, to treat patients with
acquired or inherited defects in the BRCA1 gene will, we
hypothesize, lead to signiﬁcant improvements in disease
outcome for these patients and within the otherwise aggres-
sive TN subtype.Will There Be a Use for Epigenetic Markers in
Routine Clinical Management of Breast Cancer
Patients?
The resequencing of cancer genomes has led to the
discovery of several previously unknown cancer genes.10,481058These efforts have identiﬁed more than 50 cancer genes that,
when mutated, can contribute to breast cancer development.
It is clear, however, that the large majority of these genes are
mutated in fewer than 5% of all breast cancers. Thus, the
question arises whether any of these cancer genes, when not
mutated, could be affected by epigenetic mechanisms.
Based on current knowledge, the catalog of mutated cancer
genes has a rather limited overlap with the catalog of genes
found to be epigenetically inactivated. One example is of
course the BRCA1 gene; other examples include PTEN and
CDKN2A.
The PI3KeAKT signaling pathway is commonly
enhanced in breast cancers,104 mainly through PIK3CA
mutation or ERBB2 ampliﬁcation, but to a lesser extent by
mutations in either PTEN or AKT.10,48 Clinical trials are
currently underway for testing various PI3K inhibitors
developed to target different components of the pathway.105
In the PI3K pathway, PTEN inactivation by epigenetic
mechanisms96,97 is likely to extend the use of drug inhibitors
effective for PTEN-defective cancer cells. Another way of
studying this overlap is to look at cellular pathways, such as
the CpG island promoter methylation of the PPP2R2B
gene32,33 (a phosphatase and negative regulator of AKT,
which is an important component within the PI3K pathway)
that occurs in breast cancers. In this way, epigenetic modiﬁ-
cations may target the same pathway even though the genes
affected are different from those identiﬁed by cancer genome
resequencing. In other instances, the overlap between epige-
netic and genetic changes arises within gene families, such as
in the runt-related transcription factor family genes, in which
RUNX1 is mutated by homozygous deletions,106 but only
RUNX3 (but not RUNX1 or RUNX2) is known to be inacti-
vated by epigenetic mechanisms.34,35 The RUNX gene
products are known to be transcription factors involved in
differentiation, but were recently found to localize and
interact with other proteins at the centromeres, suggesting
roles in the regulation of mitosis.107 These functional anal-
yses are potentially relevant to the ﬁndings emerging from
the systematic screening of drug sensitivity in cancer cell
lines,77 which demonstrate increased sensitivity of RUNX1-
mutated cancer cell lines to serine/threonine kinase inhibitors
of the mitosis regulators aurora kinase B, Wee1-like protein
kinase, and serine/threonine-protein kinase Chk1 (encoded
by AURKB, WEE1, and CHEK1, respectively). It might
therefore be worthwhile to determine whether the subset of
cancer cell lines without RUNX1 mutations but still showing
sensitivity to these inhibitors have acquired CpG island
promoter methylation of the RUNX3 gene.
In some cases, genes previously implicated in cancer
development have not been found to be mutated but are
frequently found inactivated in cancer by epigenetic mech-
anisms [eg, RASSF1 (alias RASSF1A), GSTP1, MGMT, and
BRMS1]. Some of these markers are potential candidates for
predicting response to drug treatment. For example, CpG
island hypermethylation of the ESR1 estrogen receptor
gene is signiﬁcantly associated with a lack of response toajp.amjpathol.org - The American Journal of Pathology
Epigenetics and Breast Cancertamoxifen.36 In breast cancer, expression states of the
estrogen and progesterone hormone receptors are both
prognostic in terms of disease outcome and predictive of
response to tamoxifen. Tamoxifen is used when hormone-
receptor expression is positive, and it has been shown to be
beneﬁcial for reducing the risk of disease relapse. The anal-
ysis of ESR1methylation could be helpful in a clinical setting
for identifying patients who will not beneﬁt from tamoxifen,
thereby sparing them from ineffective treatment. More
recently, PITX2 methylation was identiﬁed as a marker
associated with tamoxifen resistance.37 In such cases, the use
of epigenetic drugs such as 5-azacytidine (Vidaza) or deci-
tabine (5-aza-20-deoxycytidine; Dacogen), along with
histone deacetylase inhibitors such as vorinostat or romi-
depsin could be useful for overcoming tamoxifen resistance.
CpG island promoter hypermethylation of the GSTP1
gene, ﬁrst described in 1998,38 has recently been linked to
therapeutic response to doxorubicin.32 The GSTP1 gene
encodes an enzyme involved in detoxiﬁcation, and repres-
sion of GSTP1 by epigenetic mechanisms probably leads to
an accumulation of xenobiotics and carcinogens that
contributes to cancer development while enhancing the
effects of various anticancer drugs.
In this context,GSTP1methylation was found to be highly
prevalent in prostate cancer,30 and has now been validated by
other researchers as a promising marker for the early detec-
tion of prostate cancer based on noninvasive analysis of
circulating DNA from urine samples.30,108 The principle
behind the use of bodily ﬂuids for detection of DNA derived
from solid cancers is based on the direct release of DNA after
necrosis or cell lysis at the primary site of origin and, in some
cases, the capacity of this DNA to migrate to the blood
stream. In terms of breast cancer diagnosis in women, the use
of several markers (ie, RASSF1, RARB2, and APC ) along
withGSTP1 can increase the sensitivity of methylation-based
diagnosis without loss of speciﬁcity in serum samples.39
In fact, other marker panels have shown promising results
in this regard, using ductal lavage samples.109 The high
frequency of RASSF1 methylation events in breast cancers33
makes RASSF1 an ideal diagnostic marker, and RASSF1 has
also shown promise in monitoring adjuvant therapeutic
efﬁcacy.110 DNA methylation markers can be analyzed in
blood samples using powerful bisulﬁte-based PCR tech-
niques (eg, methylation-speciﬁc PCR), enabling highly
sensitive detection of methylated alleles derived from
cancer.31 This is clinically signiﬁcant, because currently no
biomarkers are available for detecting the presence of breast
cancer cells using blood-based analyses.
Conclusions
The introduction of next-generation sequencing and array-
based technologies for analyzing epigenetic states in normal
and cancerous cells holds great promise for furthering our
understanding of the roles of epigenetic changes in cancer.
Next-generation sequencing and array-based methods forThe American Journal of Pathology - ajp.amjpathol.organalyzing DNA methylation have conﬁrmed classical CpG
island promoter hypermethylation as an important mecha-
nism for inactivating tumor suppressor genes in various
types of cancers, including breast cancer.40,47 Moreover,
ﬁndings emerging from next-generation sequencing of
a breast cancer methylome, described by Hon et al,40 have
led to new discoveries wherein loss of gene-body methyl-
ation (without involving changes at promoter regions),
coupled with gains in repressive histone marks H3K27Me3
and H3K9Me3, represents a prominent mechanism by
which gene inactivation occurs in breast cancer.40 This
occurs predominantly at PMDs. Because PMDs are thought
to be important in establishing cellular identity during
differentiation,49 this mechanism could yield further insights
into the epigenetic processes underlying the origin of cancer
stem cells.
For breast cancer, there are now convincing data reported
by Fang et al47 to show that, in some cases, the epigenetic
landscape is characterized by a hypermethylated CpG island
methylator phenotype (CIMP). In this instance, the genes
affected in CIMP-associated cancers are mostly those
regulated by the PcG proteins in embryonic stem cells,
marked for repression by H3K27Me3, and the majority of
these are genes with functional roles associated with
development and cellular differentiation. The cause of the
CIMP in breast cancer is currently unknown, although
candidates have been identiﬁed in other cancer types (eg,
acquired IDH1 mutations in gliomas9). Thus, these are two
mechanistically different processes by which widespread
epigenetic changes involving gene inactivation can arise
during breast carcinogenesis. In both cases, the affected
genes tend to have functional roles in differentiation, sug-
gesting effects on stem cell properties and possibly also on
disease aggressiveness.
After the discovery that acquired mutations in epigenetic
genes can drive events in many types of cancer, including
breast cancer, the notion that epigenetic changes and genetic
mutations act cooperatively in driving disease development
has been widely discussed in the literature. We therefore
stress the ﬁnding that BRCA1, a DNA repair gene, is inac-
tivated by epigenetic mechanisms in at least 10% to 15% of
breast cancers, thus probably contributing to the accumu-
lation of genetic mutations and thereby facilitating cancer
development. Additionally, structural rearrangements may
well arise as a consequence of global DNA hypomethylation
at CpG-poor regions, in which normally repressed regions
are exposed, including those covering repetitive and trans-
posable elements. Furthermore, there is growing evidence of
a direct role for PcG proteins in maintaining genomic
stability by mediating chromatin changes at sites of DNA
damage involving DSBs.111
These ﬁndings point toward a link between defects in the
epigenetic machinery and the onset of genetic instability.
Much work remains to be done to clarify this relationship.
For example, what is the role of mutations in epigenetic
genes, how do they affect the epigenetic machinery, and are1059
Stefansson and Estellerthere phenotypic consequences with respect to genetic
instability? Additionally, the use of anticancer drugs with
DNA-damaging properties in cancers arising in BRCA1 or
BRCA2mutation carriers has attracted considerable attention,
with testing of PARP inhibitors and platinum-based drugs in
clinical trials. As we have noted, the consequences of BRCA1
inactivation by epigenetic mechanisms in sporadically
arising breast cancers are the same as for BRCA1mutations in
familial cases. It is therefore reasonable to hypothesize that
these drugs will be equally effective in sporadic cases with
acquired BRCA1 methylation as in familial cases with
inherited BRCA1 mutations. Several studies, including two
from our research group,91,97 have supported this hypothesis.
The explosion of knowledge in breast cancer genetics
enabled by the resequencing of cancer genomes and genome-
wide association studies has already begun to open up new
possibilities for treatment.77,78 However, mutation is rare in
almost all known cancer genes. Thus, identiﬁcation and
understanding of epigenetic changes in cancers hold great
promise for bringing personalized medicine to a larger
number of patientsda concept that is excellently illustrated
by BRCA1 methylation and its potential as a predictive
marker in the clinical management of patients.References
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